Therapeutic Targets Database
BIDD Pharmainformatics Databases


TTD Target ID: TTDR00267

Target Information
NamePeptide deformylase    
Type of targetClinical trial target    
Polypeptide deformylase    
DiseaseBacterial infections
[ICD9: 001-009, 010-018, 020-027, 030-041, 080-088, 090-099, 100-104   ICD10: A00-A09, A15-A19, A20-A28, A30-A49, A65-A69, A70-A74, A75-A79]
[ICD9: 084   ICD10: B50-B54]
BioChemical ClassHydrolases acting on carbon-nitrogen bonds    
EC NumberEC
UniProt IDP27251
PDB Structure1BS4; 1BS5; 1BS6; 1BS7; 1BS8; 1BSJ; 3G5K; 3G5P.    
FunctionRemoves the formyl group from the n-terminal met of newly synthesized proteins. Requires at least a dipeptide for an efficient rate of reaction. N-terminal l-methionine is a prerequisite for activity but the enzyme has broad specificity at other positions.    
QSAR ModelClick to Find Target QSAR Model.    
Cysteinesulfonic Acid[6]
Double Oxidized Cysteine[6]
Formic Acid[6]
N- (2-Acetamido)Iminodiacetic Acid[6]
N-alkyl urea hydroxamic acids[9]
NVP-PDF386 (VRC4887)[10]
Cross References 3D Structure
Related Literature
On-Line Medical Dictionary
Ref 1Characterization of a human peptide deformylase: implications for antibacterial drug design. Biochemistry. 2003 Aug 26;42(33):9952-8. To Reference
Ref 2Peptide deformylase as an antibacterial drug target: assays for detection of its inhibition in Escherichia coli cell homogenates and intact cells. Antimicrob Agents Chemother. 2001 Apr;45(4):1053-7. To Reference
Ref 3Peptide deformylase inhibitors as antibacterial agents: identification of VRC3375, a proline-3-alkylsuccinyl hydroxamate derivative, by using an integrated combinatorial and medicinal chemistry approach. Antimicrob Agents Chemother. 2004 Jan;48(1):250-61. To Reference
Ref 4Crystals of peptide deformylase from Plasmodium falciparum reveal critical characteristics of the active site for drug design. Structure. 2002 Mar;10(3):357-67. To Reference
Ref 5Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. To Reference
Ref 6Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. To Reference
Ref 7Actinonin, a naturally occurring antibacterial agent, is a potent deformylase inhibitor. Biochemistry. 2000 Feb 15;39(6):1256-62. To Reference
Ref 8Asymmetric synthesis of BB-3497--a potent peptide deformylase inhibitor. Bioorg Med Chem Lett. 2001 Oct 8;11(19):2585-8. To Reference
Ref 9N-alkyl urea hydroxamic acids as a new class of peptide deformylase inhibitors with antibacterial activity. Antimicrob Agents Chemother. 2002 Sep;46(9):2752-64. To Reference
Ref 10Comparative spectrum and activity of NVP-PDF386 (VRC4887), a new peptide deformylase inhibitor. J Antimicrob Chemother. 2003 Jan;51(1):157-61. To Reference
Ref 11Opportunities and challenges in antiparasitic drug discovery. Nat Rev Drug Discov. 2005 Sep;4(9):727-40. To Reference


Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.

Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore

All rights reserved.

Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links


Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543